1. Hillmer AM, Hanneken S, Ritzmann S, Becker T, Freudenberg J, Brockschmidt FF, Flaquer A, Freudenberg-Hua Y, Jamra RA, Metzen C, Heyn U, Schweiger N, Betz RC, Blaumeiser B, Hampe J, Schreiber S, Schulze TG, Hennies HC, Schumacher J, Propping P, Ruzicka T, Cichon S, Wienker TF, Kruse R, Nothen MM. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 2005;77:140-148.
2. Hillmer AM, Brockschmidt FF, Hanneken S, Eigelshoven S, Steffens M, Flaquer A, Herms S, Becker T, Kortum AK, Nyholt DR, Zhao ZZ, Montgomery GW, Martin NG, Muhleisen TW, Alblas MA, Moebus S, Jockel KH, Brocker-Preuss M, Erbel R, Reinartz R, Betz RC, Cichon S, Propping P, Baur MP, Wienker TF, Kruse R, Nothen MM. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 2008;40:1279-1281.
3. Inui S, Itami S. Androgen actions on the human hair follicle: perspectives. Exp Dermatol 2013;22:168-171.
5. Bayne EK, Flanagan J, Einstein M, Ayala J, Chang B, Azzolina B, Whiting DA, Mumford RA, Thiboutot D, Singer II, Harris G. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol 1999;141:481-491.
7. Fazekas AG, Lanthier A. Metabolism of androgens by isolated human beard hair follicles. Steroids 1971;18:367-379.
8. Itami S, Kurata S, Takayasu S. 5 alpha-reductase activity in cultured human dermal papilla cells from beard compared with reticular dermal fibroblasts. J Invest Dermatol 1990;94:150-152.
9. Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol 1998;156:59-65.
10. Randall VA, Thornton MJ, Hamada K, Messenger AG. Mechanism of androgen action in cultured dermal papilla cells derived from human hair follicles with varying responses to androgens in vivo. J Invest Dermatol 1992;98(6 Suppl):86S-91S.
11. Hamada K, Randall VA. Inhibitory autocrine factors pro-duced by the mesenchyme-derived hair follicle dermal papi-lla may be a key to male pattern baldness. Br J Dermatol 2006;154:609-618.
12. Randall VA, Thornton MJ, Messenger AG. Cultured dermal papilla cells from androgen-dependent human hair follicles (e.g. beard) contain more androgen receptors than those from non-balding areas of scalp. J Endocrinol 1992;133:141-147.
13. Nelson AM, Loy DE, Lawson JA, Katseff AS, Fitzgerald GA, Garza LA. Prostaglandin D2 inhibits wound-induced hair follicle neogenesis through the receptor, Gpr44. J Invest Der-matol 2013;133:881-889.
14. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis G. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med 2012;4:126ra34.
15. Villarreal-Villarreal CD, Sinclair RD, Martinez-Jacobo L, Garza-Rodriguez V, Rodriguez-Leon SA, Lamadrid-Zertuche AC, Rodriguez-Gutierrez R, Ortiz-Lopez R, Rojas-Martinez A, Ocampo-Candiani J. Prostaglandins in androgenetic alope-cia in 12 men and four female. J Eur Acad Dermatol Venereol 2019;33:e214-e215.
16. Blume-Peytavi U, Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, Reygagne P, Messenger A; European Consensus Group. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011;164:5-15.
17. Lee WS, Ro BI, Hong SP, Bak H, Sim WY, Kim DW, Park JK, Ihm CW, Eun HC, Kwon OS, Choi GS, Kye YC, Yoon TY, Kim SJ, Kim HO, Kang H, Goo J, Ahn SY, Kim M, Jeon SY, Oh TH. A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification. J Am Acad Dermatol 2007;57:37-46.
18. Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008;59:547-566.
19. Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, Trakatelli M, Finner A, Kiesewetter F, Trüeb R, Rzany B, Blume-Peytavi U; European Dermatology Forum (EDF). Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Der-matol Ges 2011;9 Suppl 6:S1-S57.
20. Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, Trakatelli M, Tosti A, Del Marmol V, Piraccini BM, Nast A, Blume-Peytavi U. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol 2018;32:11-22.
21. Lee WS, Lee HJ, Choi GS, Cheong WK, Chow SK, Gabriel MT, Hau KL, Kang H, Mallari MR, Tsai RY, Zhang J, Zheng M. Guidelines for management of androgenetic alopecia based on BASP classification: the Asian Consensus Commit-tee guideline. J Eur Acad Dermatol Venereol 2013;27:1026-1034.
22. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004;150:186-194.
23. Baden HP, Grassi A, Kvedar J. The effect of the drug minoxidil on hair growth. In: Rogers GE, Reis PJ, Ward KA, Marshall RC, editor. The biology of wool and hair. London: Chapman and Hall; 1989. p. 217-226.
24. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004;50:541-553.
25. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002;47:377-385.
26. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011;65:1126-1134. e2.
27. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007;57:767-774.
29. Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012;66:794-800.
30. Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bima-toprost 0.03% solution. J Drugs Dermatol 2011;10:795-798.
31. Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther 2014;52:842-849.
32. Olsen EA, Whiting DA, Savin R, Rodgers A, Johnson-Levo-nas AO, Round E, Rotonda J, Kaufman KD; Male Pattern Hair Loss Study Group. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol 2012;67:379-386.
33. Adil A, Godwin M. The effectiveness of treatments for andro-genetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol 2017;77:136-141. e5.
34. Shin JW, Chung EH, Kim MB, Kim TO, Kim WI, Huh CH. Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. J Dermatol 2019;46:139-143.
35. Rossi A, Cantisani C, Scarno M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther 2011;24:455-461.
36. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5alpha-reductase inhibitors. Steroids 2010;75:109-153.
37. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, Cho HK, Sim WY, Lew BL, Lee WS, Park HY, Hong SP, Ji JH. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010;63:252-258.
38. Gubelin Harcha W, Barboza Martinez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014;70:489-498. e3.
40. Lee SY, Chun SW, Kim JB, Ro BI. A case of combination therapy with finasteride and low dose dutasteride in the treatment of androgenetic alopecia. Korean J Dermatol 2017;55:147-148.
41. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J; Finasteride Study Group. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003;61:791-796.
42. Yanagisawa M, Fujimaki H, Takeda A, Nemoto M, Sugimoto T, Sato A. Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia. Clin Res Trials 2019;5:1-5.
43. Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male andro-genetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol 2019;99:12-17.
44. Overstreet JW, Fuh VL, Gould J, Howards SS, Lieber MM, Hellstrom W, Shapiro S, Carroll P, Corfman RS, Petrou S, Lewis R, Toth P, Shown T, Roy J, Jarow JP, Bonilla J, Jacobsen CA, Wang DZ, Kaufman KD. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 1999;162:1295-1300.
45. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichen-berg JS. Adverse effects and safety of 5-alpha reductase inhi-bitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthet Dermatol 2016;9:56-62.
46. Traish AM. Post-finasteride syndrome: a surmountable chal-lenge for clinicians. Fertil Steril 2020;113:21-50.
48. Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol 2019;58:759-776.
49. Atanaskova Mesinkovska N, Bergfeld WF. Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment Dermatol Clin 2013;31:119-127.
50. Lengg N, Heidecker B, Seifert B, Trueb RM. Dietary supple-ment increases anagen hair rate in women with telogen efflu-vium: results of a double-blind, placebo-controlled trial. The-rapy 2007;4:59-65.